Skip to content
← Index board

Health Optimization Index

Quercetin

Nick’s assessment
Promising
Research evidence
C, mixed evidence
Attention
20.8 / 100▲ Rising this week
6.6/ 10

BioHarmony score

Quercetin scores 6.5–7.0/10 Worth trying because bioavailability is poor, headline longevity and antiviral claims outpace human evidence, and the best replicated signals (allergic rhinitis, small BP reductions, uric acid) are narrow.

Read the full report Benefits, risks and practical guidance.

Read Nick’s assessment Why it earned this rating

The 6.5–7.0/10, Worth trying score reflects honest tension between a wide mechanistic story and a narrow band of replicated human signals. Quercetin earns its supplement shelf space for allergic rhinitis on phytosome, small BP reductions, chronic prostatitis support, and hyperuricemia adjuncts. It does not earn the senolytic, antiviral, MCAS, cancer, H pylori, or broad longevity language used in much of the marketing. The form matters more than the dose: phytosome and glucosylated forms outperform plain dihydrate by roughly 20 times. The most consequential risks are interaction-mediated and opportunity-cost-driven rather than intrinsic toxicity.

✅ Best for: Adults with seasonal or perennial allergic rhinitis trying quercetin phytosome 200 mg/day during exposure windows. Prehypertensive or stage 1 hypertensive adults adding 500 to 730 mg/day quercetin alongside diet, exercise, and clinical monitoring. Men with chronic prostatitis or chronic pelvic pain syndrome trialing 500 mg twice daily for 1 month under urology guidance. Adults with elevated uric acid or gout history considering a 4-week quercetin trial alongside the standard urate-lowering and dietary approach. Older inflamed adults curious about senolytic-class exposure who lack prescription access to dasatinib and accept that quercetin alone is not proven senolytic.

❌ Avoid if: Pregnant, trying to conceive, or breastfeeding without clinician oversight; pediatric users outside a clinician-directed allergy protocol. On warfarin, DOACs, antiplatelets, transplant drugs, chemotherapy, or narrow therapeutic index medications without explicit review. On statins handled by OATP1B1 (especially pravastatin) where interaction can raise plasma drug exposure. On dasatinib or other tyrosine kinase inhibitors outside a clinician-supervised senolytic protocol. Substituting quercetin for proven care in COVID, cancer, H pylori, MCAS, or serious infection. Planned surgery or dental procedure within 2 weeks. Buying generic liposomal quercetin products without product-specific human PK data when phytosome or EMIQ alternatives exist.

Share your experience

Your answers are optional and help other readers — they never change my score. How community input works.

Tried it in real life?

How would you assess it?

Favorable is the strongest rating, followed by Promising, then Experimental. Overhyped means the claims outrun the evidence or interest is fading.

Make a 12-month prediction Will it rise or fall in the Index?

Choose a direction and your confidence. Correct predictions earn leaderboard points.

Your 12-month call on Quercetin
How sure are you?

Your prediction is final once submitted. We’ll check it in 12 months. See the leaderboard →

Updated Sep 21, 2026 How the Index ranks →

Educational information, not medical advice. Ask a qualified clinician about risks and interactions. Independent ratings: no affiliate links, sponsored placements or paid rankings.